Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E27.18 EPS (ttm)1.82 Insider Own- Shs Outstand2.61B Perf Week-3.92%
Market Cap129.11B Forward P/E15.46 EPS next Y3.20 Insider Trans- Shs Float2.38B Perf Month-3.19%
Income4.81B PEG3.36 EPS next Q- Inst Own9.90% Short Float0.08% Perf Quarter0.14%
Sales38.97B P/S3.31 EPS this Y18.40% Inst Trans0.01% Short Ratio1.16 Perf Half Y12.08%
Book/sh24.36 P/B2.03 EPS next Y1.43% ROA4.50% Target Price56.60 Perf Year-3.91%
Cash/sh3.29 P/C15.04 EPS next 5Y8.10% ROE7.80% 52W Range42.16 - 55.57 Perf YTD12.08%
Dividend1.61 P/FCF- EPS past 5Y-4.00% ROI7.00% 52W High-10.97% Beta1.11
Dividend %3.25% Quick Ratio1.30 Sales past 5Y1.80% Gross Margin67.80% 52W Low17.33% ATR1.09
Employees113496 Current Ratio1.80 Sales Q/Q12.20% Oper. Margin19.60% RSI (14)46.73 Volatility1.72% 1.48%
OptionableYes Debt/Eq0.26 EPS Q/Q-6.40% Profit Margin12.60% Rel Volume0.57 Prev Close49.76
ShortableYes LT Debt/Eq0.24 EarningsJul 30 BMO Payout46.90% Avg Volume1.65M Price49.47
Recom1.70 SMA20-1.43% SMA50-1.21% SMA2002.74% Volume945,148 Change-0.58%
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Sep-23-08Downgrade Credit Suisse Neutral → Underperform
Oct-24-07Initiated Bernstein Mkt Perform
Sep-06-07Initiated UBS Neutral
Jul-18-07Upgrade HSBC Securities Neutral → Overweight
Jun-14-07Reiterated Banc of America Sec Buy $50 → $48
Jul-02-15 08:51AM  Never mind Greece, Europe will beat the U.S.: Strategist
Jul-01-15 04:12PM  What Is Beyond Vision-Loss Blockbuster For Regeneron? at Investor's Business Daily
03:46PM  Analysts Battle Over MannKind -- but Who's Right? at Investopedia
09:30AM  The Zacks Analyst Blog Highlights: Delhaize Group, Sanofi and Luxfer Holdings - Press Releases
Jun-30-15 11:27AM  MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin at TheStreet
10:42AM  Roche 'High Efficacy' MS Drug Succeeds In Trials at Investor's Business Daily
10:19AM  Is Grexit Inevitable? 3 Stocks to Buy - Analyst Blog
08:00AM  New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol PR Newswire
Jun-29-15 12:50PM  3 European Stocks Paying Juicy Dividends at Kiplinger
Jun-26-15 04:03AM  New Sanofi CEO to unveil five-year plan in November -unions Reuters
Jun-24-15 01:33PM  Eurozone Business Activity Is at Its Highest Level in 4 Years
09:30AM  Pep Boys, Acacia Research, Sanofi, Unilever and Continental Aktiengesellschaft highlighted as Zacks Bull and Bear of the Day - Press Releases
Jun-23-15 12:31PM  Viehbacher to head $2bn Bertarelli healthcare fund at Financial Times
10:30AM  Greece Deal Likely? 3 Stock Picks - Analyst Blog
03:00AM  Former Sanofi CEO Makes Science Comeback With Bertarelli Fund at Bloomberg
Jun-22-15 03:17PM  Top Europe Stocks Rally On Greece Bailout Hopes at Investor's Business Daily
Jun-19-15 01:41PM  Biotechs about to break out: Pro
Jun-16-15 04:50PM  Sanofi Starts Dosing in Phase I/II Study on Olipudase Alfa - Analyst Blog
12:39PM  We've Only Seen This Contrarian Buy Signal One Other Time Since 2009 at Forbes
Jun-15-15 04:30PM  Alnylam Reveals Positive Initial Data on RNAi Drug ALN-CC5 - Analyst Blog
11:06AM  Bad News from Greece as It Postpones Grexit, but GREK Is Up 1.08%
10:16AM  Regeneron: Don't Worry, Be Happy at
08:00AM  Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients Business Wire
Jun-12-15 09:00AM  Steven Nissen, Conflicts Of Interest, And The New Cholesterol Drugs at Forbes
Jun-11-15 01:00PM  Johns Hopkins gets seat at table for grantmaking by French drugmaker Sanofi at
10:10AM  S&P downgrades Greece ratings: Pro
08:59AM  Krispy Kreme pops; Lululemon founder sells stake; Nike inks NBA deal
08:10AM  Retail sales rebound; Nike's big NBA score; LA minimum wage hike
Jun-10-15 05:35PM  Amgen Cholesterol Drug Repatha Wins FDA Panel Vote at Investor's Business Daily
04:40PM  Regeneron/Sanofi's Praluent Gets Positive FDA Panel Vote - Analyst Blog
04:30PM  MannKind Corporation Sinks: CFO Says 'We're Not There Yet' With Afrezza
04:27PM  French biotech giant banks on innovation with area hospitals at
03:44PM  UPDATE 3-FDA panel backs Sanofi/Regeneron cholesterol drug with limits Reuters
03:26PM  Live Blog: FDA Panel For Amgen's Cholesterol Drug Repatha at Forbes
01:35PM  Esperion Therapeutics: Why Regeneron Decision is Bad News at
01:15PM  State Street Gets Into the Currency Hedged ETF Game
10:52AM  FDA Panel Clears Product Path For Sanofi, Regeneron Pharmaceuticals
10:16AM  Why Regeneron is Getting Clobbered at
09:10AM  Netflix hits fresh 52-week high; Apple Music probe; HCC surges on merger
08:15AM  Wall Street's funk; Target's dividend slip up; Apple's antitrust problem
07:21AM  Two drugs target 'bad' cholesterol: CEO
Jun-09-15 07:53PM  Out With the Old? Sanofi Wishes -- Overheard at The Wall Street Journal
06:40PM  FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia PR Newswire
06:30PM  FDA Advisory Committee Recommends Approval of Regeneron and Sanofi's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia PR Newswire
06:09PM  Regeneron/Sanofi Cholesterol Drug Wins FDA Panel Vote at Investor's Business Daily
06:09PM  Regeneron Cholesterol Fighter Gets FDA Panel's Backing, 13-3
06:31AM  FDA targets 'bad' cholesterol drug
Jun-08-15 04:55PM  Sanofi (SNY) Presents Data from Extension Studies on Toujeo - Analyst Blog
03:10PM  Brigham study shows Sanofi diabetes drug safe for heart at
02:15PM  No heart, other safety risks seen with Sanofi diabetes drug- study Reuters
11:10AM  Regeneron/Sanofi's PCSK9 Drug Praluent Set for FDA Panel - Analyst Blog
06:00AM  Top former Sanofi executive to join Cambridge drugmaker Alnylam at
04:39AM  Alnylam Names Former Sanofi Manager as Chief Business Officer at Bloomberg
12:08AM  FDA Queues Up Review of Anti-Cholesterol Drugs at The Wall Street Journal
Jun-07-15 04:30PM  Here's How Lee Iacocca Wants To Cure Diabetes at Forbes
09:40AM  New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels at 24/7 Wall St.
Jun-06-15 01:58PM  Lilly to Introduce Lantus Biosimilar in Europe in Third Quarter at Bloomberg
05:33AM  FDA Reviews Anti-Cholesterol Drugs at The Wall Street Journal
Jun-05-15 05:16PM  FDA weighs approval of first-in-class cholesterol drug
10:44AM  The Fight Against Cholesterol Heats Up; FDA Panel Considers Drugs from Regeneron, Amgen Next Week at
Jun-04-15 05:25PM  Fighting 'bad' cholesterol
03:44PM  Wedbush: Regulus Therapeutics Will Quadruple In Price Within 12 Months
09:31AM  Merck's Quest To Revive The Market For Insomnia Drugs at Forbes
01:00AM  FDA Grants Breakthrough Therapy Designation for Genzymes Olipudase Alfa Business Wire
Jun-03-15 07:00AM  MannKind's inhaled insulin drug proves hard for diabetics to get at Los Angeles Times
Jun-01-15 02:20PM  Two Watertown medical device firms get $26M investment at
12:29AM  U.S. Drug Shortages Frustrate Doctors, Patients at The Wall Street Journal
May-31-15 10:30PM  Drug Shortages Frustrate Doctors, Patients at The Wall Street Journal
10:29PM  U.S. Drug Shortages Frustrate Doctors, Patients
May-29-15 04:53PM  R&D Can Be A Critical Factor In Generating Future Profits
11:43AM  Rare But Severe Facial Damage With Soft-Tissue Dermal Fillers, FDA Warns at Forbes
May-28-15 02:07PM  These dozen Mass. companies are honed in on drugs for rare diseases (BBJ photo gallery) at
01:56PM  Moody's: High barriers to entry spur M&A activity in orphan drug sector at Moody's
10:22AM  Sanofi Announces Men With Advanced Prostate Cancer in England Will Continue to Have Access to Cabazitaxel (Jevtana®) PR Newswire
May-27-15 09:18AM  Retrophin Sells FDA Voucher to Sanofi at The Wall Street Journal
06:00AM  Genzyme Commemorates World MS Day with Awareness and Educational Events Globally Business Wire
May-26-15 08:00AM  Genzyme to Present Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) Data at CMSC Business Wire
04:30AM  NeuroVive Asia Signs Collaboration Agreement with Sanofi for the Development and Commercialization of Ciclomulsion® in South Korea Business Wire
01:00AM  Fight over hot new cholesterol drugs may be won in milligrams Reuters
May-25-15 09:00AM  Prince Edward Island funds treatment with AUBAGIO(TM) for Relapsing Remitting Multiple Sclerosis CNW Group
May-22-15 04:20PM  Sanofis Global Head for Prostate Drug, Zhen Su, Leaves Company at Bloomberg
01:23PM  In Massachusetts, biotech firms account for a lot of value but few jobs at
07:23AM  Amgen first to win EU backing for new kind of cholesterol drug Reuters
May-21-15 04:27PM  3 Top IBD 50 Stocks Hit New All-Time Highs
10:30AM  Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog
01:00AM  Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis PR Newswire
May-20-15 07:00AM  Genzymes Announces Launch of Expression of Hope III Art Exhibit Business Wire
06:58AM  Orexigen CEO Pledged To Keep Data Secret, But Not From Himself at Forbes
May-19-15 04:40PM  Regeneron/Sanofi Announce Positive Data on Dupilumab - Analyst Blog
03:13PM  MannKind stock jumps on positive report about inhaled insulin at Los Angeles Times
12:04PM  Amgen cholesterol drug could get EU green light this week Reuters
11:00AM  VCEL: Vericel Is Too Cheap To Ignore
08:53AM  5 Big Pharma Stocks to Trade for Breakout Gains at TheStreet
08:00AM  Genzyme Receives Innovation Award from the National Organization for Rare Disorders (NORD) for the Development of Cerdelga® Business Wire
01:40AM  MannKind's Huge Short Interest Sets Up Contrarian's Dream Buy at Forbes
May-18-15 04:21PM  Healthcare Winners and Losers: May 18, 2015
12:30PM  Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference PR Newswire
May-15-15 04:19PM  5 Things MannKind's Management Wants You to Know at Investopedia
May-14-15 04:45PM  Sanofi (SNY) Exercises Celiac Disease Program Option - Analyst Blog
May-13-15 11:00AM  Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerDec 24Buy398.7930,00211,964,50122,859,144Dec 29 05:40 PM
Sanofi10% OwnerDec 23Buy392.23171,45767,251,14222,829,142Dec 29 05:40 PM
Sanofi10% OwnerOct 16Buy335.35122,12740,955,05722,657,685Oct 20 05:45 PM
Sanofi10% OwnerOct 15Buy328.16158,36851,970,26522,535,558Oct 17 05:05 PM
Sanofi10% OwnerJul 15Buy314.92129,10040,656,17622,204,841Jul 17 05:50 PM
Sanofi10% OwnerJul 14Buy318.18150,00047,726,79722,075,741Jul 15 05:45 PM
Sanofi10% OwnerJul 11Buy315.41150,00047,311,83621,925,741Jul 15 05:45 PM
Sanofi10% OwnerJul 10Buy311.08175,00054,439,07321,775,741Jul 14 05:46 PM
Sanofi10% OwnerJul 09Buy308.27195,00060,112,31121,600,741Jul 10 05:45 PM
Sanofi10% OwnerJul 08Buy311.67153,00047,685,74321,405,741Jul 10 05:45 PM
Sanofi10% OwnerJul 07Buy312.90256,70080,320,79521,252,741Jul 08 05:42 PM